可手术肺癌分子残留病灶检测临床应用专家共识(2026版)OA

Detection of molecular residual disease(MRD)based on circulating tumor DNA holds signif-icant application value for prognostic assessment and recurrence monitoring in resectable lung cancer.However,current practices lack standardized guidelines regarding core aspects such as target populations,technical ap-proaches,timing of monitoring,and adaptive treatment strategies.To address this,the Chinese Thoracic Oncol-ogy Group(CTONG)YOUNG established a"Working Group on Expert Consensus for Molecular Residual Disease in Resectable Lung Cancer".Based on a systematic review of the latest international advancements and objective evidence-based medical data,the group formulated the Expert Consensus on Clinical Application of Molecular Residual Disease Detection in Resectable Lung Cancer(2026 Edition).This consensus focuses on a systematic and in-depth discussion of key issues,including the selection of target populations for MRD detec-tion,optimization of technical detection pathways,determination of perioperative and postoperative longitudinal follow-up time points,and the clinical value of MRD status in guiding escalation or de-escalation strategies for both treatment-naïve patients and those receiving neoadjuvant therapy.In addition,the consensus specifies the essential components for standardizing MRD detection reports.The aim is to provide an objective scientific basis and decision-making reference for thoracic surgeons and oncologists in clinical practice,thereby advancing the field of resectable lung cancer toward a new era of individualized precision management.